FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 801 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR ¿Qué son los biosimilares para el tratamiento del cáncer? November 30, 2021 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC June 24, 2026 When You and Your Child Have VHL: 8 Ways to Cope August 11, 2020 FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... September 15, 2023 Load more HOT NEWS Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... Melanoma Cells Are More Likely to Spread after a Stopover in... Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy...
